Ashton Thomas Private Wealth LLC Sells 2,980 Shares of Pfizer Inc. $PFE

Ashton Thomas Private Wealth LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 6.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,467 shares of the biopharmaceutical company’s stock after selling 2,980 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Pfizer were worth $1,102,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Pfizer by 38.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,182,830 shares of the biopharmaceutical company’s stock valued at $29,027,000 after buying an additional 330,019 shares during the period. Koshinski Asset Management Inc. grew its stake in shares of Pfizer by 9.4% in the 1st quarter. Koshinski Asset Management Inc. now owns 23,208 shares of the biopharmaceutical company’s stock valued at $588,000 after buying an additional 1,995 shares during the period. Finally, Mather Group LLC. grew its stake in shares of Pfizer by 9.8% in the 1st quarter. Mather Group LLC. now owns 22,185 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 1,978 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $24.32 on Thursday. The company has a market capitalization of $138.26 billion, a P/E ratio of 12.94, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.64. The business has a 50-day simple moving average of $24.82 and a two-hundred day simple moving average of $24.25.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. UBS Group restated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.